Drug Trial Radar · NCT05711615
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Feb 6, 2024
Primary completion
May 3, 2027
Study completion May 3, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Feb 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also enhance the activity of chemo- and radiotherapy. There is some pre-clinical evidence in animal models that combining peposertib with liposomal doxorubicin can shrink or stabilize certain types of cancer for longer than either drug alone, but it is not known if this will happen in people. Combination therapy with liposomal doxorubicin and peposertib may be effective in treating patients with advanced sarcoma.
Conditions
- Metastatic Dedifferentiated Liposarcoma
- Metastatic Leiomyosarcoma
- Metastatic Myxofibrosarcoma
- Metastatic Sarcoma
- Metastatic Synovial Sarcoma
- Metastatic Undifferentiated Pleomorphic Sarcoma
- Unresectable Dedifferentiated Liposarcoma
- Unresectable Leiomyosarcoma
- Unresectable Myxofibrosarcoma
- Unresectable Sarcoma
- Unresectable Synovial Sarcoma
- Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy ProcedureProcedure
Undergo tissue biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo CT scan
Echocardiography TestProcedure
Undergo ECHO
Magnetic Resonance ImagingProcedure
Undergo MRI
Multigated Acquisition ScanProcedure
Undergo MUGA
Pegylated Liposomal Doxorubicin HydrochlorideDrug
Given IV
PeposertibDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT) rateTime frame: Up to 28 days
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Los Angeles General Medical Center
Los Angeles, California · Recruiting
USC / Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UCHealth University of Colorado Hospital
Aurora, Colorado · Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida · Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Active not recruiting
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois · Active not recruiting
University of Chicago Medicine-Orland Park
Orland Park, Illinois · Active not recruiting
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland · Recruiting
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Suspended
Washington University School of Medicine
St Louis, Missouri · Recruiting
Siteman Cancer Center-South County
St Louis, Missouri · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
UT MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Virginia Cancer Center
Charlottesville, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.